A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Efficacy and Safety of SAR339658 in Patients With Active Moderate to Severe Ulcerative Colitis (UC)
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
Price : $35 *
At a glance
- Drugs Vatelizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms FUSCIA
- Sponsors Sanofi
- 20 May 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 08 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2016 to 1 May 2016.
- 26 Mar 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.